Sulfated glycosaminoglycans were extracted from arteriosclerotic and adjacent nonarterlosclerotlc areas of human aortas from persons ages 28 to 83 years; the glycosaminoglycans were compared with the cholesterol and trlglycerlde content of the tissues. Sulfated glycosaminoglycans were Isolated after proteolytlc digestion of defatted arterial tissue and were quantified after reductive labeling with NaB^V The amount of glycosaminoglycans In the aorta Increased with the age of the person and the cholesterol content (degree of arteriosclerosis) of the aorta. 14 Proteoheparan sulfate, on the other hand, is thought to be involved in the control of smooth muscle cell growth, because cell-associated heparan sulfate from confluent arterial smooth muscle cells 15 and arterial endothelial cells 1617 specifically inhibits the proliferation of arterial smooth muscle cells.
1 -2 Proliferating arterial smooth muscle cells synthesize and secrete increased amounts of proteoglycans, 3 which are capable of interacting with lipoproteins. 4 - 7 The complexes thus formed cause the accumulation of low density lipoprotein in the arterial wall and the subsequent development of arteriosclerosis.
Proteoglycans containing chondroitin sulfate, dermatan sulfate, and heparan sulfate glycosaminoglycans have been detected in human 8 and in mammalian*-12 arteries. Such proteoglycans have been characterized as individual macromolecular species by chemical and physicochemical procedures. 10 - 13 Extracellular proteochondroitin sulfate/dermatan sulfate may constitute a viscoelastic gel that regulates the flux of macromolecular plasma constituents into the vessel wall.
14 Proteoheparan sulfate, on the other hand, is thought to be involved in the control of smooth muscle cell growth, because cell-associated heparan sulfate from confluent arterial smooth muscle cells 15 and arterial endothelial cells 1617 specifically inhibits the proliferation of arterial smooth muscle cells.
it has been established that the content of sulfated glycosaminoglycans in the artery increases as arteriosclerosis progresses, 1819 but no information is available about corresponding changes in the content of heparan sulfate. In view of the antiproliferative activity of heparan sulfate and its potential role in the pathogenesis of arteriosclerosis, 13 the quantitative evaluation of sulfated glycosaminoglycans is of special interest. The present study shows that increasing cholesterol content during the development of arteriosclerosis in the human aorta is accompanied by decreasing amounts of heparan sulfate and an increase in chondroitin sulfate/dermatan sulfate.
Methods

Materials
Chondroitin ABC lyase was purchased from Seikagaku, Tokyo, Japan and heparttln lyase, from Miles Scientific, Munich, FRG. Sodium 3 H-borohydride (specific radioactivity 500 mCi/mmol) was obtained from Amersham Buchler (Braunschweig, FRG). Whatman DE 52 cellulose ion exchanger was from Whatman Limited, United Kingdom, and Sephadex G 50 fine was from Pharmacia (Freiburg, FRG). All chemicals were purchased from Merck (Darmstadt, FRG) and Serva (Heidelberg, FRG).
Isolation and Fractlonatlon of Sulfated Glycosaminoglycans
Thoracic aortas were obtained from the Institute of Pathology, University of MQnster. Twenty-five human aortas were obtained at autopsy within 8 hours after death. Segments of the aortas ranging from the left arterial subclavia to the sixth arteria intercostalis were used for the studies. Throughout the preparation of samples, all aortas were kept on ice. The specimens were freed from fat and adhering connective tissue and were rinsed with cold saline. After removal of the adventitia, macroscopically normal appearing and adjacent arteriosclerotic specimens (on the average 3 cm apart) ranging from 0.2 to 2.5 g were selected for analysis. Focal intimal thickening with the appearance of fatty streaks and/or fibrous plaques were regarded as arteriosclerotic. Plaques with hemorrhage, ulceration, or mineralization were not included. The samples were minced into 5x5 mm pieces, were delipldated with chloroform/methanol (2:1), and were dried under vacuum in the presence of paraffin. Total lipids were recovered after solvent removal and were analyzed for cholesterol and triglycerides by standard methods. 20 The defatted samples were subjected to proteolysis in 0.1 M acetate buffer (pH 5.8) containing 0.5% papain (200 U/g), 0.05% EDTA, and 0.005 M cystein at 65°C for 24 hours. After papain digestion, which completely dissolved the arterial tissue, the glycosaminoglycans were precipitated with cetytpyridinium chloride at a final concentration of 1% (wt/vol). The cetylpyridinium-glycosaminoglycan precipitate was dissolved in 2 ml of 1 M MgCI 2 and was precipitated with 2.5 volumes of ethanol containing potassium acetate (final concentration 1 % [wt/ vol]). The precipitated potassium salts of the glycosaminoglycans were centrifuged and dissolved in distilled water. Glycosaminoglycans were precipitated by the addition of cetylpyridinium chloride in the presence of MgCI 2 to final concentrations of 1% wt/vol, and 0.125 M, respectively. Under these conditions, hyaluronate remained in solution. The insoluble cetylpyridinium salts of glycosaminoglycans were pelleted by centrifugation, were dissolved in 1 M MgCI 2 , were precipitated with ethanol containing potassium acetate (final concentration, 1% wt/vol), were washed twice with ethanol and once with ether, and then were dried under a stream of air. Glycosaminoglycans were radiolabeled by reduction with NaB 3 H 4 according to the procedure of Glaser and Conrad. 21 After destruction of excess borohydride, glycosaminoglycans were recovered by gel filtration on a Sephadex G 50 column (0.8x50 cm) equilibrated with 1 M NaCI at ambient temperature. Material eluting with 1 M NaCI between Kav=0 and Kav=0.1 was pooled and, after adding 0.5 mg unlabeled chondroitin sulfate, was dialyzed against 6 M urea in 0.1 M Tris-HCI, pH 7.0. For separation of glycosaminoglycans by ion exchange chromatography, the dialyzed pools were applied to a 2 ml DE 52 column equilibrated with the above buffer at ambient temperature. After elution of unbound material with 5 ml of buffer, bound glycosaminoglycans were eluted with a linear gradient of NaCI (0 to 0.6 M, 10 g/10 g) in the above buffer. 
Further Procedures
Chondroitin suffate and heparan sulfate were assayed enzymatically as described elsewhere. 22 After enzyme digestions, samples were thermally inactivated and subjected to gel filtration on a Sephadex G 50 fine column (0.8x50 cm) equilibrated and eluted with 1 M NaCI. The appearance of 3 H-labeled material in the total volume (V,) was indicative of degradation. Radioactivity was measured with a liquid scintillation counter (Packard A 4430, Packard Instruments GmbH, Frankfurt, FRG) by using Instagel (Packard Instruments GmbH) as the scintillation medium. 
Results
The total cholesterol and triglyceride content and the total sulfated glycosaminoglycans were analyzed in grossly normal appearing regions and in adjacent arteriosclerotic areas of 25 human aortas from subjects 28 to 83 years old. The total cholesterol and triglyceride content was quantified by enzymatic analysis according to standard procedures. The total content of sulfated glycosaminoglycans was determined after quantitative release of chondroitin sulfate, dermatan sulfate, and heparan sulfate from the respective proteoglycans by proteolytic digestion and complete dissolution of the arterial wall followed by /3-elimination and 3 H-labeling of the monosaccharide residue (xylose) at the reducing end of the polysaccharide chain. 3 H-radioactMty reflected the number of glycosamincglycan molecules. All values were expressed as milligrams or 3 H-cpm/g dry weight of tissue. No effort was made to quantify native proteoglycans, because these are not quantitatively extractable from tissue with dissociative solvents.
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Total Glycosamlnoglycan Content Increases with Age and Degree of Arteriosclerosis
Plots of the radioactivity of 3 H-glycosaminoglycans against age or cholesterol content of the aorta indicated that the glycosaminoglycan content increased proportionally ( Figure 1) . The age-dependent increase appeared more pronounced in arteriosclerotic tissue than in normal areas, but the correlation coefficient was less than 0.7, so that the difference was not significant. No correlation between triglyceride and 3 H-glycosaminoglycan contents was found (data not shown).
Amount of Heparan Sulfate Relative to Total Glycosamlnoglycan Decreases, and Chondroitin Sulfate/Dermatan Sulfate Increases, with Increased Age and Cholesterol Content
Heparan sulfate and chondroitin sulfate/dermatan sulfate were separated on the basis of their different anionic charges (Figure 2 ). Heparan sulfate was distinguished by Fraction Nunixr Figure 2 . Separation of 3 H-heparan sulfate and IH-chondrottin sulfate/dermatan sulfate by ion exchange chromatography. The total su(fated glycosaminoglycans were isolated and labeled by reductive ^-elimination In the presence of NaB 3 H 4 . 5X10 3 cpm were applied to a DE 52 column (2 ml) and eluted with a NaCI gradient (50 g of 50 mM Tris-HCI buffer, pH 7.0 and 50 g of 50 mM Tris-HCI buffer containing 0.6 M NaCI). Bars represent fractions that were pooled and used for further analysis.
its sensitivity to heparitinase, chondroitin sulfate/dermatan sulfate, by its resistance to heparitinase and its susceptibility to chondroitinase ABC.
When age and cholesterol-dependent changes in the grycosaminoglycan fraction were sought, it became clear that the relative proportion of heparan sulfate decreased linearly with increasing age and increasing cholesterol content in both normal and arteriosclerotic regions of the arteries. The correlation coefficients were r=-0.91 for normal, and r=-0.95 for arteriosclerotic segments (Figures 3A and 3B) . From the data in Figure 3 , it can be calculated that the amount of heparan sulfate relative to total glycosaminoglycans decreased from 4 1 % to 20% with increasing age and from 41 % to 23% with increasing cholesterol content.
In contrast, the chondroitin sulfate/dermatan sulfate fraction showed a marked linear increase with increasing cholesterol content and age, the correlation coefficients being r=0.92 and r=0.95, respectively, for normal and arteriosclerotic areas of the arteries (Figures 4A and 4B ).
Discussion
The grycosaminoglycan content of arterial tissue and its alteration during arteriosclerosis has been the subject of several reports (See references 23 and 24 and the references cited therein). However, no information is available on changes in grycosaminoglycan concentration in relation to the lipid content of human arteries. Recently YlaHerttuala et al. 24 studied the composition of glycosaminoglycans in human coronary arteries and found that with increasing age and in advanced arteriosclerotic lesions there were increases in the proportion of chondroitin sulfate/ dermatan sulfate and decreases in heparan sulfate. However, the arteriosclerotic lesions were not characterized with respect to their lipid content.
In our research, a significant age-and cholesteroldependent increase in the percentage composition of chondrottin sulfate and dermatan sulfate, and a corresponding decrease in heparan sulfate, was demonstrated. Macroscopically normal appearing and arteriosclerotic specimens were included in the analysis. However, since even ostensibly undiseased segments of vessels may contain early arteriosclerotic lesions, cholesterol content, which is the characteristic feature of arteriosclerotic lesions, was considered the definitive parameter for the degree of arteriosclerosis.
In our study, quantification of the individual glycosaminoglycans was based on selective 3 H-labeling of the reducing terminus of each polysaccharide chain. Therefore, the radioactivity does not reflect the glycosaminoglycan concentration, but rather the number of grycosaminoglycan chains. Consequently, the relative increase in chondroitin sulfate/dermatan sulfate and the decrease in heparan sulfate with increasing age and increasing degree of arteriosclerosis indicate corresponding changes in the number of grycosaminoglycan chains. However, when the chain length of heparan sulfate isolated from areas with low cholesterol content was compared with that from areas with high cholesterol content, no significant differences were found, as judged from the elution profile of the heparan sulfate chains on Sephacryl S 300 (Hollmann, unpublished observations). Likewise, the lengths of chondroitin sulfate and dermatan sulfate chains were not significantly different, although in some cases longer chondroitin sulfate/dermatan sulfate chains were isolated On the other hand, the decrease in heparan sulfate with increasing severity of arteriosclerosis ( Figure 4 ) is of special interest, because arterial smooth muscle cells produce a heparan sulfate species with antiproliferative activity. 15 Thus, heparan sulfate is thought to be involved in controlling the growth of smooth muscle cells. 151817 However, it remains to be established whether loss of heparan sulfate can cause accelerated cell proliferation, which is known to be an early event in the development of arteriosclerotic plaques. Atherogenesis and the concomitant changing of the glycosaminoglycan pattern may be initiated by hyperiipoproteinemia. This assumption is supported by the finding that the accumulation of plasma low density lipoprotein in the arterial wall after hypercholesterolemia induces altered glycosaminoglycan synthesis in medial smooth muscle cells. 26 
